Fibroblast Growth Factor-23, Cardiovascular Prognosis, and Benefit of Angiotensin-Converting Enzyme Inhibition in Stable Ischemic Heart Disease

OBJECTIVES: This study sought to test 2 hypotheses: 1) fibroblast growth factor (FGF)-23 identifies patients with stable ischemic heart disease (SIHD) at high risk of cardiovascular events independent of clinical factors, renal function, and established cardiovascular biomarkers; and 2) FGF-23 ident...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Udell, Jacob A., Morrow, David A., Jarolim, Petr, Sloan, Sarah, Hoffman, Elaine B., O’Donnell, Thomas F., Vora, Amit N., Omland, Torbjørn, Solomon, Scott D., Pfeffer, Marc A., Braunwald, Eugene, Sabatine, Marc S.
Format: Artigo
Langue:Inglês
Publié: 2014
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4213068/
https://ncbi.nlm.nih.gov/pubmed/24727254
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jacc.2014.03.026
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires